Patient Experience

Home / Our therapy areas / Oncology / Patient Experience

AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Through relentless innovation and a commitment to scientific discovery we are catalysing changes in the practice of medicine to transform the patient experience. By working with the community, we can empower patients and caregivers, and are able to evolve the way cancer is treated by accelerating the uptake of the latest advancements.

Through collaborations with researchers, academia, healthcare providers, governments, industry and scientific organisations, patients and their families, we are uncovering unique insights on how we can establish new standards of screening, diagnostics and treatment.

I am passionate about developing medicines to improve the outcomes for patients with cancer and developing the skills and experience of the people within my team.

Susan Galbraith Executive Vice-President, Oncology R&D
Learn more about Susan Galbraith

In the spotlight

New Normal, Same Cancer

 

In 2020, we partnered with global patient coalitions around the world to launch New Normal, Same Cancer. This programme raises awareness of the impact of the COVID-19 pandemic on cancer care and calls for those experiencing new symptoms or are waiting to attend routine screening appointments not to wait any longer to contact their doctor. 
 

Read more about New Normal, Same Cancer

Lung Ambition Alliance

 

Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance.  Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care

 

Read more about the Lung Ambition Alliance

Patients as people first

Our commitment to patients

Our longstanding commitment to patients has led us to reimagine our patient-focused ways of working, as we embed it across every aspect of our company to deliver the healthcare experience and outcomes people care about most so they can enjoy fulfilling lives

Read more about our commitment to patients here

Explore our Oncology pillars

Clinical Strategy

Our clinical strategy aims to transform survival.

Medicines: Portfolio and Pipeline

With our portfolio, our pipeline and our people, we aim to revolutionise cancer care.

Our People & Culture

Our people, passion and innovation drive us.